


HIV-1 infection: When the virus and the host play hide and seek




Asier Sáez-Ciri3n, PhD
Unit3 HIV Inflammation et Persistence
Institut Pasteur



HIV-1 infection starts with transmission of limited number of founder viruses



Nature Reviews | Microbiology




Nature Reviews | Microbiology

Several factors determine the selection of the founder viruses:



- Sensitivity to autologous antibodies
- Sensitivity to IFN
- Level of glycosylation
- Fitness to infect target cells

HIV-1 replication cycle: multiple targets for antiretroviral therapy



However antiretroviral therapy does not target the integrated provirus

HIV persists in cellular reservoirs despite durable antiretroviral treatment



Time on treatment :

65.7 year



Chomont et al unpublished



Establishment of HIV reservoir is a multifaceted process

Cell susceptibility to infection

Balance between restriction and dependency factors





Restriction factors

Dependency factors

- APOBEC3 proteins
- TRIM5α proteins
- BST-2/Tetherin
- MX2
- SAMHD1

Brass and al., Science. 2008, 319:921-6




Establishment of HIV reservoir is a multifaceted process

Cell susceptibility to infection

Survival to HIV infection

Resistance to HIV induced apoptosis

Escape immune surveillance



FDC cytokines → enhance HIV replication in TFH cells and increase proliferative rate of infected TFH cells viral persistence, since germinal centers are relatively devoid of cytolytic CD8⁺ T cells.

Establishment of HIV reservoir is a multifaceted process


Cell susceptibility to infection

Survival to HIV infection

Cell Persistence


Half life

Turnover




Two models to explain persistence on cART

Low level HIV replication





Survival and cell proliferation



cART does not completely block viral replication (and in particular cell-to-cell transmission)





Viral particles are released by infected cells that persist by homeostatic proliferation

HIV infects cells from the immune system that contribute to spread and persistence




Spread and establishment of reservoirs is a fast process

SIV reservoir established within 3 days?




Development of Immune responses during acute HIV-1 infection

Concomitant establishment of viral reservoirs and development of immune responses




Very early events and innate immunity



Nature Reviews | Immunology

M.Altfeld, et al, 2011, Nat Rev Immunol




Nature Reviews | Immunology

McMichael et al 2010 Nat Rev Immunol

- Innate immunity constitutes a first barrier of defense against HIV infection:
 - NK cells have direct antiviral activity and promote adaptive immunity
 - Type I IFN production by pDCs
- Early and strong cytokine response may contribute to viral dissemination, establishment of reservoir and may decide the fate of immune responses

The CD8+ T cell response contributes to partially control HIV infection




CD8+ T cells produce soluble anti-HIV factors (b-chemokines, CAF(?)) and eliminate infected cells through cytotoxic mechanisms.

-Coincidence between the appearance of HIV specific CD8+ T cells and control of primary infection.



-Depletion of CD8+ T cells during SIV infection leads to increased viral load.

-Association between Class I HLAs and level of viremia





Haase, Nature, 2010, 464, 217-223

Antibodies against HIV: multiple ways to tackle the infection



Ultimately these defenses are inefficient to control the virus

Virus evolves to escape immune responses



1% of variability/year in each infected individual


Global flu



HIV
one patient




HIV in Congo




Viral diversity 1996

Adapted from R Weiss Nature 2003
and B Korber Br Med Bull 2001




Inefficient control of infection leads to exhaustion of immune responses and damage of lymphoid structures

Disruption of reticulin network in T cell zone




Estes et al. Seminars Immunol 2008, 20, 181-86



Freeman et al JEM, 2006, 203, 2223-2227


Loss of organized B cell follicles




Kök et al. Mucosal Immunol 2015, 8, 127-40

HIV associated chronic inflammation

HIV production
HIV replication




HIV-associated fat
Metabolic syndrome



CMV
Excess pathogens




Loss of regulatory
cells




Inflammation
↑ Monocyte activation
↑ T cell activation
Dyslipidemia
Hypercoagulation

Microbial
translocation




Co-morbidities
Aging

Immune activation and HIV pathogenesis



All the same, but all different in response to HIV


Extensive interindividual variability in response to HIV (*susceptibility to virus, transmission and disease progression...*)





Differences in viral set points, rates of CD4 T cells decline, levels of viremia, inflammation/immune activation, emergence of CTL escape mutants or development of opportunistic infections

A small proportion of HIV-1 infected people show « natural resistance » to infection (HESN) or to disease progression (HIC,LTNP)

Distinct HIV/SIV infection outcomes



Adapted from G. Silvestri



Three steps to control HIV-1 infection

- 1- Limit viral reservoirs
- 2- Develop efficient mechanisms to control viral rebound
- 3- Restrain immune activation/inflammation

HIV/AIDS: an outstanding global health problem

~ 36.9 million people living with HIV

cART introduction changed the face of the epidemic, however:

- 2.0 million new infections/year
- 1.2 million deaths/year
- 60% of patients still in need of life-long cART

Patients request alternative strategies




Fig. 2 : Nombre de découvertes de séropositivité VIH, France, 2003-2012 (Source : Déclaration obligatoire du VIH, données corrigées au 31/12/2012, InVS)






Fig. 4 : Nombre de découvertes de séropositivité VIH par mode de contamination et par pays de naissance, France, 2003-2012 (Source : Déclaration obligatoire du VIH, données corrigées au 31/12/2012, InVS)



Cascade de la prise en charge en France en 2010



Chez les patients suivis au moins 3 ans, 88% du temps correspond à un suivi adéquat